Navigation Links
UnderPenetrated Latin American Varicose Vein Treatment Device Market Will Grow Rapidly Through 2021

TORONTO, June 20, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the Latin American varicose vein treatment device market is severely underpenetrated, with less than 5 percent of the eligible patient pool estimated to have undergone treatment in 2012. This can be primarily attributed to the elective nature of these procedures; governments and patients will continue to place more focus on treating life-threatening conditions or those that would more severely impact their quality of life. Nonetheless, as the Latin American economy strengthens, patients will have more disposable income and greater access to insurance, which will spur rapid adoption of varicose vein treatments through 2021.

(Logo: )

When varicose veins are treated, many Latin Americans will continue to opt for the least expensive option: surgical vein stripping. Although this procedure is both invasive and painful, it is often covered by public or private insurance, unlike many other alternatives such as endovenous ablation. This is important in the cost-conscious environment in Latin America.

Competitors have therefore struggled to earn adoption of more expensive devices that can be used for less painful varicose vein treatments. For example, manufacturers of endovenous laser ablation devices have experienced the highest rates of adoption in Argentina, but are struggling in other Latin American markets. However, this difficulty is even more pronounced in the sclerotherapy market.

"Sclerotherapy is popular, and getting even more popular," said MRG Analyst Tonya Martin. "However, competitors have been unable to harness this popularity due to difficulties in gaining approval for sclerosants, poor distribution networks and a lack of consensus on the appropriate agent to be used in each sclerotherapy treatment. As a result, most Latin American physicians are using low-cost off-brand sclerosants or importing agents illegally."

Because sclerotherapy accounts for more than half of varicose vein treatment volumes in Latin America, spurring adoption of legal and approved sclerosants is a key opportunity for competitors going forward.

Millennium Research Group's Latin American Markets for Varicose Vein Treatment Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for endovenous ablation devices and surgical stripping devices in Argentina, Brazil, Colombia and Mexico. Procedure volumes are also provided for sclerotherapy and phlebectomy treatments. Supplemental country coverage is also available for Chile, Peru and Venezuela, as well as in aggregate for the rest of the Latin American countries.

About Millennium Research Group
Millennium Research Group (, a Decision Resources Group company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group

Alex Jablokow
Millennium Research Group



SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
2. Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
3. Mega Trends Foster Investment, Innovation and Expansion in Latin America, Finds Frost & Sullivan
4. Latin America Medical Device Market Reports
5. Pi2 Solutions 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia
6. OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons
7. Economic Growth In Latin America Fueling Strong Revenue Growth For Interventional Cardiology Devices
8. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
9. Olympus Introduces the Worlds Only Articulating HD 3D Laparoscopic Surgical Video System
10. Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
11. Latin American Electronic Medical Record Market: Key Trends and Forecasts until 2017
Post Your Comments:
(Date:11/24/2015)... Nueva York , 24 de noviembre ... fabricante del Avery Breathing Pacemaker System, se complace ... MD; Ph.D. como consultor clínico. ... --> Foto -   ... doctor Jonzon es un fisiólogo y consultor en ...
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many ... the doctor uses other traditional cutting tools, such as the scalpel and high-speed drill, ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November 12th ... which patients are or are not eligible for bariatric surgery. The article explains that ... are more than 100 pounds overweight, or have a BMI of 35 and over ...
(Date:11/24/2015)... ... 2015 , ... It takes only three to five seconds to make a ... first impression be positive and reflects business values. If a client starts with a ... to return. They will also share their thoughts about a business with others, which ...
(Date:11/24/2015)... ... 2015 , ... Cancer patients, survivors, caregivers, family members and ... taping of the next CURE Connections® video series on Saturday, Dec. ... at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE Connections, ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
Breaking Medicine News(10 mins):